Gossamer Bio/$GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Ticker
$GOSS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
145
ISIN
US38341P1021
Website
Gossamer Bio Metrics
BasicAdvanced
$309M
-
-$0.23
1.82
-
Price and volume
Market cap
$309M
Beta
1.82
52-week high
$1.55
52-week low
$0.66
Average daily volume
2.1M
Financial strength
Current ratio
5.713
Quick ratio
5.485
Long term debt to equity
-3,230.944
Total debt to equity
-3,244.592
Interest coverage (TTM)
-4.92%
Profitability
EBITDA (TTM)
-54.19
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-41.13%
Operating margin (TTM)
-43.96%
Effective tax rate (TTM)
-1.77%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
-12.68%
Return on equity (TTM)
-500.57%
Valuation
Price to revenue (TTM)
2.472
Price to book
-49.44
Price to tangible book (TTM)
-49.44
Price to free cash flow (TTM)
33.91
Free cash flow yield (TTM)
2.95%
Free cash flow per share (TTM)
4.01%
Growth
Earnings per share change (TTM)
-75.71%
3-year earnings per share growth (CAGR)
-58.26%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Bulls say / Bears say
Gossamer Bio's strategic partnership with Chiesi Farmaceutici S.p.A. includes a $160 million development cost reimbursement and shared costs for global clinical development, enhancing financial stability and accelerating seralutinib's development. (finance.yahoo.com)
Seralutinib's clean long-term safety profile differentiates it from competitors like Merck's Winrevair, potentially making it a preferred choice among severe PAH patients. (markets.businessinsider.com)
Analysts have maintained 'Buy' ratings on Gossamer Bio, citing progress in seralutinib trials and strategic market expansion, with price targets up to $10.00. (markets.businessinsider.com)
The Goldman Sachs Group lowered its price target for Gossamer Bio from $8.00 to $7.00, indicating tempered expectations for the stock's performance. (defenseworld.net)
Barclays maintained a 'Hold' rating on Gossamer Bio with a price target of $0.50, reflecting cautious sentiment regarding the company's near-term prospects. (markets.businessinsider.com)
Despite a narrower-than-expected Q4 loss, Gossamer Bio reported a net loss of $56.5 million for 2024, highlighting ongoing financial challenges. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
Business Wire·4 weeks ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $309M as of July 11, 2025.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of July 11, 2025.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.